Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification by Jintanat Ananworanich, Nicolas Chomont, James L.K. Fletcher, Suteeraporn Pinyakorn, Alexandra Schuetz, Irini Sereti, Rungsun Rerknimitr, Robin Dewar, Eugene Kroon, Claire Vandergeeten, Rapee Trichavaroj, Nitiya Chomchey, Thep Chalermchai, Nelson L. Michael, Jerome H. Kim, Praphan Phanuphak, Nittaya Phanuphak

“…They were randomised 1 : 1 to HAART (tenofovir/emtricitabine/efavirenz, n=31) or megaHAART, a standard regimen intensified by raltegravir/maraviroc (n=31), during the first 24 weeks of therapy. …”
Get full text

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial. by Cissy Kityo, Alexander J Szubert, Abraham Siika, Robert Heyderman, Mutsa Bwakura-Dangarembizi, Abbas Lugemwa, Shalton Mwaringa, Anna Griffiths, Immaculate Nkanya, Sheila Kabahenda, Simon Wachira, Godfrey Musoro, Chatu Rajapakse, Timothy Etyang, James Abach, Moira J Spyer, Priscilla Wavamunno, Linda Nyondo-Mipando, Ennie Chidziva, Kusum Nathoo, Nigel Klein, James Hakim, Diana M Gibb, A Sarah Walker, Sarah L Pett, REALITY trial team

“…At 48 weeks, the nucleoside reverse transcriptase inhibitor (NRTI) mutation K219E/Q (p = 0.004) and the non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations K101E/P (p = 0.03) and P225H (p = 0.007) were less common in virus from participants with raltegravir-intensified ART, with weak evidence of less intermediate- or high-level resistance to tenofovir (p = 0.06), abacavir (p = 0.08), and rilpivirine (p = 0.07). …”
Get full text

Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC vs. B/F/TAF: the DEBATE... by Andrea Cossarizza, Alessandro Cozzi-Lepri, Marco Mattioli, Annamaria Paolini, Anita Neroni, Sara De Biasi, Domenico Lo Tartaro, Rebecca Borella, Lucia Fidanza, Lara Gibellini, Barbara Beghetto, Enrica Roncaglia, Giulia Nardini, Jovana Milic, Marianna Menozzi, Gianluca Cuomo, Margherita Digaetano, Gabriella Orlando, Vanni Borghi, Giovanni Guaraldi, Giovanni Guaraldi, Cristina Mussini, Cristina Mussini

“…BackgroundThe aim of this randomized clinical trial (RCT) was to compare immunological changes in virally suppressed people living with HIV (PLWH) switching from a three-drug regimen (3DR) to a two-drug regimen (2DR).MethodsAn open-label, prospective RCT enrolling PLWH receiving a 3DR who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir/lamivudine (DTG/3TC) was performed. …”
Get full text

Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria by Nicaise Ndembi, Fati Murtala-Ibrahim, Monday Tola, Jibreel Jumare, Ahmad Aliyu, Peter Alabi, Charles Mensah, Alash’le Abimiku, Miguel E. Quiñones-Mateu, Trevor A. Crowell, Soo-Yon Rhee, Robert W. Shafer, Ravindra Gupta, William Blattner, Manhattan E. Charurat, Patrick Dakum

“…A total of 2140 (36.1%) received tenofovir (TDF); 2662 (44.9%) zidovudine (AZT); and 1126 (19.0%) stavudine (d4T). …”
Get full text

Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting by Nongodo Firmin Kaboré, Armel Poda, Jacques Zoungrana, Ollo Da, Laura Ciaffi, Aoua Semdé, Issouf Yaméogo, Adrien B. Sawadogo, Eric Delaporte, Nicolas Meda, Sophie Limou, Amandine Cournil

“…Regarding the ART exposure in patients with normal baseline eGFR, zidovudine (AZT) with protease inhibitor (PI) (− 4.7[− 7.7;-1.6] ml/min/1.73m2, p = 0.002), tenofovir (TDF) + PI (− 13.1[− 17.4;-8.7] ml/min/1.73m2, p < 0.001), TDF without PI (− 3.2[− 5.0;-1.4] ml/min/1.73m2, p < 0.001), stavudine (d4T) + PI (− 8.5[− 14.6–2.4] ml/min/1.73m2, p = 0.006) and d4T without PI (− 5.0[− 7.6–2.4] ml/min/1.73m2, p < 0.001) were associated with poorer eGFR progression. …”
Get full text

Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial by Elizabeth M Irungu, PhD, Kenneth K Mugwanya, ProfPhD, Nelly R Mugo, ProfMMed, Elizabeth A Bukusi, ProfPhD, Deborah Donnell, ProfPhD, Josephine Odoyo, MPH, Elizabeth Wamoni, BSc, Sue Peacock, MS, Jennifer F Morton, MPH, Kenneth Ngure, ProfPhD, Mary Mugambi, BA, Irene Mukui, MPH, Gabrielle O'Malley, ProfPhD, Jared M Baeten, ProfMD

“…PrEP continuation was 57% at 1 month, 44% at 3 months, and 34% at 6 months, and 12% of those who missed a refill returned later for PrEP re-initiation. Tenofovir diphosphate was detected in 68 (96%) of 71 blood samples collected from a randomly selected subset of participants. …”
Get full text

PERFIL DE PACIENTES EM USO DE TERAPIA DUPLA COM DOLUTEGRAVIR E LAMIVUDINA, COORTE RETROSPECTIVA DE VIDA REAL by Ana Caroline Coutinho Iglessias, José Valdez Ramalho Madruga, Mariza Vono Tancredi, João Paulo dos Santos Gouveia, Lucas Rocker Ramos, Camila de Albuquerque Moraes, Erika Maria do Nascimento Kalmar, Marli Sasaki, Mylva Fonsi, Patrícia Rady Müller, Tatiany Viviany Gonçalves Souza, Daniel Gleison Carvalho, Roberta Schiavon Nogueira

“…Principais esquemas prévios a TD: Tenofovir (TDF) + 3TC + DTG 166 (43%), Abacavir (ABC) + 3TC + DTG 44 (11,4%), Zidovudina (AZT) + 3TC + DTG 32 (8,3%), TDF + 3TC + Efavirenz (EFZ) 30 (7,8%), ABC + 3TC + EFZ 29 (7,5%) e 82 outros esquemas. …”
Get full text

FATORES ASSOCIADOS ÀS MUDANÇAS DA TERAPIA ANTIRRETROVIRAL INICIAL EM UM CENTRO DE REFERÊNCIA NA BAHIA – BRASIL by Monaliza Cardozo Rebouças, Leonardo Bandeira Cerqueira Zollinger, Scarlat Marjory de Oliveira Moura, Laiane dos Santos Ribeiro Machado, Rafaella Tambone Barral, Maria Fernanda Bahia Bacellar Souza, Thiago Pinho Cordeiro Araújo, Simone murta Martins, Marcio Pires dos Santos, José Adriano Goes Silva, Anderson Vinicius Mota de Souza, Fabianna Márcia Maranhão Bahia, Carlos Roberto Brites Alves

“…A TARV inicial mais frequente foi a combinação de lamivudina (3TC) + tenofovir (TDF) + Dolutegravir (DTG) (60,4%), seguido de 3TC+TDF associado ao Efavirenz (25,0%) ou Atazanavir/ritonavir (4,9%). …”
Get full text

Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir‑era by Willy Le Roi Togna Pabo, Debimeh Njume, Roland Ndip Ndip, Desiré Takou, Maria-Mercedes Santoro, Collins Chenwi, Grace Beloumou, Ezechiel Ngoufack Jagni Semengue, Alex Durand Nka, Aude Christelle Ka'e, Georges Teto, Beatrice Dambaya, Sandrine Djupsa, Raymond Babila Nyasa, Davy Hyacinthe Gouissi Anguechia, Cedric Kamta, Lionel Bala, Virginie Lambo, Samuel Martin Sosso, Vittorio Colizzi, Carlo Federico Perno, Joseph Fokam, Alexis Ndjolo

“…Of note, optimized ART guided by mutational profile (AOR=0.05, p=0.002) was protective. Moreover, full Tenofovir+Lamivudine+Dolutegravir efficacy was predicted in 77% and 62% of APHI respectively after first- and second-line failure. …”
Get full text

APLASIA DE MEDULA ÓSSEA HEPATITE B-RELACIONADA: RELATO DE CASO by MT Souza, IA Campinas, LP Menezes, RO Coelho, BB Cal, ME Pelicer, BB Arnold, LO Cantadori, RD Gaiolla, L Niero-Melo

“…Embora o quadro clínico de entrada tenha sido frustro, o exame sorológico levou ao diagnóstico de AMOAH por VHB, com pronta demanda para tratamento (Tenofovir e Suporte Transfusional). Discussão: AA é entidade rara, com incidência estimada entre 1 - 6 casos/milhão/ano, podendo ser congênita ou adquirida, sem preferência entre sexos, com acometimento bimodal entre adulto jovem e idosos. …”
Get full text

Maternal ART throughout gestation prevents caudate volume reductions in neonates who are HIV exposed but uninfected by Abdulmumin Ibrahim, Abdulmumin Ibrahim, Fleur L. Warton, Fleur L. Warton, Samantha Fry, Mark F. Cotton, Sandra W. Jacobson, Sandra W. Jacobson, Joseph L. Jacobson, Joseph L. Jacobson, Christopher D. Molteno, Francesca Little, Andre J. W. van der Kouwe, Andre J. W. van der Kouwe, Andre J. W. van der Kouwe, Barbara Laughton, Ernesta M. Meintjes, Ernesta M. Meintjes, Ernesta M. Meintjes, Martha J. Holmes, Martha J. Holmes

“…Mothers with HIV received standard care fixed drug combination ART (Tenofovir/Efavirenz/Emtricitabine). Infants were imaged unsedated on a 3T Skyra (Siemens, Erlangen, Germany) at mean GA equivalent of 41.5 (± 1.0) weeks. …”
Get full text

Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels by Haneesha Mohan, Monica Guzman Lenis, Evelyn Y. Laurette, Oscar Tejada, Tanvi Sanghvi, Kit-Yi Leung, Lindsay S. Cahill, John G. Sled, Paul Delgado-Olguín, Nicholas D.E. Greene, Andrew J. Copp, Lena Serghides

“…DTG was administered with 50 mg/kg tenofovir+33.3 mg/kg emtricitabine. Fetal phenotypes were determined, and maternal and fetal folate levels were quantified by mass-spectrometry. …”
Get full text

Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques by Ivana Massud, Susan Ruone, Maria Zlotorzynska, Richard Haaland, Patrick Mills, Mian-er Cong, Kristen Kelley, Ryan Johnson, Angela Holder, Chuong Dinh, George Khalil, Yi Pan, Colleen F. Kelley, Travis Sanchez, Walid Heneine, J. Gerardo García-Lerma

“…We investigated willingness to use a single oral pill before or after sex among men who have sex with men (MSM) and assessed the biological efficacy of a potent antiretroviral combination containing elvitegravir (EVG), emtricitabine (FTC), and tenofovir alafenamide (TAF). Methods: Data on willingness to use single-dose PrEP or PEP were obtained from the 2017 cycle of the American Men's Internet Survey (AMIS), an annual online behavioral surveillance survey of MSM in the United States. …”
Get full text

Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study by Dorward, J, Sookrajh, Y, Khubone, T, van der Molen, J, Govender, R, Phakathi, S, Lewis, L, Bottomley, C, Maraj, M, Lessells, RJ, Naidoo, K, Butler, CC, Van Heerden, R, Garrett, N

“…The median age was 38 years (IQR 32–45), and the median time on ART was 3·9 years (2·0–6·4) years, with most people receiving efavirenz (178 624 [98·7%] people) and tenofovir (178 148 [98·4%]). By Feb 28, 2022, 121 174 (67·0%) of 180 956 people had transitioned to first-line dolutegravir at a median of 283 days (IQR 203–526). …”

Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients by Maria Bañó, Maria Bañó, Constanza Morén, Constanza Morén, Sergio Barroso, Sergio Barroso, Diana Luz Juárez, Diana Luz Juárez, Mariona Guitart-Mampel, Mariona Guitart-Mampel, Ingrid González-Casacuberta, Ingrid González-Casacuberta, Judith Canto-Santos, Judith Canto-Santos, Ester Lozano, Ester Lozano, Agathe León, Enric Pedrol, Òscar Miró, Ester Tobías, Ester Tobías, Josep Mallolas, Jhon F. Rojas, Francesc Cardellach, Francesc Cardellach, Esteban Martínez, Gloria Garrabou, Gloria Garrabou

“…We assessed two different PEP regimens according to their composition to ascertain if they were the cause of tolerability issues and derived toxicity.Methods: We analyzed reasons for PEP discontinuation and main secondary effects of treatment withdrawal, mtDNA content from peripheral blood mononuclear cells and metabolic profile, before and after 28 days of PEP, in 23 patients classified depending on PEP composition: one protease inhibitor (PI) plus Zidovudine/Lamivudine (PI plus AZT + 3TC; n = 9) or PI plus Tenofovir/Emtricitabine (PI plus TDF + FTC; n = 14).Results: Zidovudine-containing-regimens showed an increased risk for drug discontinuation (RR = 9.33; 95% CI = 1.34–65.23) due to adverse effects of medication related to gastrointestinal complications. …”
Get full text

BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase... by Karina Butler, Jamie Inshaw, Deborah Ford, Sarah Bernays, Karen Scott, Julia Kenny, Nigel Klein, Anna Turkova, Lynda Harper, Eleni Nastouli, Sara Paparini, Rahela Choudhury, Tim Rhodes, Abdel Babiker, Diana Gibb, on behalf of the PENTA team

“…Further trials of SCT in settings with infrequent VL monitoring and with other antiretroviral drugs such as tenofovir alafenamide, which has a long intracellular half-life, and/or dolutegravir, which has a higher barrier to resistance, are planned. …”
Get full text